ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.730,62
-0,26%
Dow Jones
42.283,78
0,26%
Euro vs US Dollar
1,11632
-0,11%
Bitcoin
65.629,66
0,69%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Protara Therapeutics Inc (TARA)

  7. Protara Therapeutics Inc (TARA) News

TARA

Protara Therapeutics (TARA)

Protara Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TARA
DatumZeitQuelleÜberschriftSymbolFirma
13/09/202402h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/09/202401h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
09/09/202414h05GlobeNewswire Inc.Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
09/09/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral SupportNASDAQ:TARAProtara Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
30/08/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
06/08/202422h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TARAProtara Therapeutics Inc
06/08/202414h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
06/08/202414h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
06/08/202414h00GlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:TARAProtara Therapeutics Inc
18/07/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
12/07/202401h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
24/06/202423h06GlobeNewswire Inc.Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/06/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
10/06/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
31/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
24/05/202401h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
21/05/202414h00GlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:TARAProtara Therapeutics Inc
18/05/202401h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
11/05/202400h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
09/05/202422h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TARAProtara Therapeutics Inc
02/05/202414h00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
05/04/202414h04GlobeNewswire Inc.Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingNASDAQ:TARAProtara Therapeutics Inc
05/04/202414h02GlobeNewswire Inc.Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionNASDAQ:TARAProtara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TARA

Kürzlich von Ihnen besucht

BOV
OPIM11
Opportunity Fundo Invest...
LSE
IN90
Euro.bk 27
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten